CN Patent

CN120983628A — 纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途

Assigned to Eirion Therapeutics Inc · Expires 2025-11-21 · 0y expired

What this patent protects

本公开提供用于治疗和/或预防某些皮肤病况(特别地，包含毛发变灰)的新型技术。此外，本公开提供以下见解：纤溶酶原激活物抑制剂‑1(PAI‑1)抑制剂可适用于治疗和/或预防某些皮肤病况，并且尤其适用于治疗和/或预防毛发变灰。

USPTO Abstract

本公开提供用于治疗和/或预防某些皮肤病况(特别地，包含毛发变灰)的新型技术。此外，本公开提供以下见解：纤溶酶原激活物抑制剂‑1(PAI‑1)抑制剂可适用于治疗和/或预防某些皮肤病况，并且尤其适用于治疗和/或预防毛发变灰。

Drugs covered by this patent

Patent Metadata

Patent number
CN120983628A
Jurisdiction
CN
Classification
—
Expires
2025-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Eirion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.